Regulation of Interleukin‐2 Induced Soluble Fas Ligand Release from Human Peripheral Blood Mononuclear Cells

References

• Bergmann‐Leitner E. S., Abrams S. I. Positive and negative consequences of soluble Fas ligand produced by an antigen‐specific CD4 + T cell response in human carcinoma immune interactions. Cell. Immunol. 2001; 209: 49–62, [CSA]
   PubMedGoogle Scholar
• Bönig H., Banning U., Hannen M., Kim Y. M., Verheyen J., Mauz‐Körholz C., Körholz D. Transforming growth factor‐beta 1 suppresses interleukin‐15‐mediated interferon‐gamma production in human T lymphocytes. Scand. J. Immunol. 1999; 50: 612–618, [CROSSREF]
   PubMedGoogle Scholar
• Brown S. B., Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J. Immunol. 1999; 162: 480–485, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dilloo D., Laws H. J., Hanenberg H., Körholz D., Nürnberger W., Burdach S. E. G. Induction of two distinct natural killer‐cell populations, activated T cells and antineoplastic cytokines, by interleukin‐2 therapy in children with solid tumors. Exp. Hematol. 1994; 22: 1081–1088, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Eneslatt K., Rantapaa‐Dahlqvist S., Uddhammar A., Sundqvist K. G. The regulation of FasL expression—a distinguishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE. J. Clin. Immunol. 2001; 21: 183–192, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Friesen C., Herr I., Krammer P. H., Debatin K.‐M. Involvement of the CD95 (APO‐1/Fas) receptor/ligand system in drug‐induced apoptosis in leukemia cells. Nat. Med. 1996; 2: 574–577, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fulda S., Los M., Friesen C., Debatin K.‐M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer 1998; 76: 105–114, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Girard D., Gosselin J., Heitz C., Paquin R., Beaulieu A. D. Effects of interleukin‐2 on gene expression in human neutrophils. Blood 1995; 86: 1170–1176, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gollob J. A., Kawasaki H., Ritz J. Interferon‐gamma and interleukin‐4 regulate T cell interleukin‐12 responsiveness through the differential modulation of high‐affinity interleukin‐12 receptor expression. Eur. J. Immunol. 1997; 27: 647–652, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase‐mediated release of human Fas ligand. J. Exp. Med. 1995; 182: 1777–1783, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Körholz D., Banning U., Bönig H., Grewe M., Schneider M., Mauz‐Körholz C., Klein‐Vehne A., Krutmann J., Burdach S. The role of interleukin‐10 in interleukin‐15 mediated T‐cell activation. Blood 1997; 90: 4513–4520, [CSA]
   PubMedGoogle Scholar
• Mauz‐Körholz C., Dietzsch S., Schippel P., Banning U., Körholz D. Molecular mechanisms of hyperthermia‐ and cisplatin‐induced cytotoxicity in T cell leukemia. Anticancer Res. 2003; 23: 2643–2648, [CSA]
   PubMedGoogle Scholar
• Miller J. S., Tessmer‐Tuck J., Blake N., Lund J., Scott A., Blazar B. R., Orchard P. J. Endogenous IL‐2 productin by natural killer cells maintain cytotoxic and proliferative capacity following retroviral‐mediated gene transfer. Exp. Hematol. 1997; 25: 1140–1148, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Müller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li‐Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M., Krammer P. H. p53 Activates the CD95 (APO‐1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998; 188: 2033–2045, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Olencki T., Finke J., Tubbs R., Tuason L., Greene T., McLain D., Swanson S. J., Herzog P., Stanley J., Edinger M., Budd G. T., Bukowski R. M. Immunomodulatory effects of interleukin‐2 and interleukin‐4 in patients with malignancy. J. Immunother. Emphas. Immunol. 1996; 19: 69–80, [CSA]
   PubMed Web of Science ®Google Scholar
• Schaafsma M. R., Falkenburg J. H., Landegent J. E., Duinkerken N., Osanto S., Ralph P., Kaushansky K., Wagemaker G., Van Damme J., Willemze R. In vivo production of interleukin‐5, granulocyte‐macrophage‐colony‐stimulating factor, macrophages colony‐stimulating factor, and interleukin‐6 during intravenous administration of high‐dose interleukin‐2 in cancer patients. Blood 1991; 78: 1981–1987, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schandene L., Alonso Vega C., Willems F., Gerard C., Delvaux A., Velu T., Devos R., de Boer M., Goldman M. B7/CD28‐dependent IL‐5 production by human resting T cells is inhibited by IL‐10. J. Immunol. 1994; 152: 4368–4374, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schwartzberg L. S., Petak I., Stewart C., Turner P. K., Ashley J., Tilman D. M., Douglas L., Tan M., Billups C., Mihalik R., Weir A., Tauer K., Shope S., Houghton J. A. Modulation of the Fas signalling pathway by IFN‐γ in therapy of colon cancer: phase I trial and correlative studies of IFN‐γ, 5‐Fluorouracil, and leucovorin. Clin. Cancer Res. 2002; 8: 2488–2498, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• van Haelst Pisani C., Kovach J. S., Kita H., Leiferman K. M., Gleich G. J., Silver J. E., Dennin R., Abrams J. S. Administration of interleukin‐2 (IL‐2) results in increased plasma concentrations of IL‐5 and eosinophilia in patients with cancer. Blood 1991; 78: 1534–1538
   Google Scholar
• Verheyen J., Bönig H., Kim Y. M., Banning U., Mauz‐Körholz C., Kramm C., Körholz D. Regulation of interleukin‐2 induced interleukin‐5 and interleukin‐13 production in human peripheral blood mononuclear cells. Scand. J. Immunol. 2000; 51: 45–53, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Verheyen J., Bönig H., Banning U., Shin D. I., Mauz‐Körholz C., Körholz D. Co‐operation of IL‐1 and IL‐2 on T‐cell activation in mononuclear cell cultures. Immunol. Invest. 2001; 30: 289–302, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar